{"database": "lobbying", "table": "lobbying_activities", "rows": [[2260510, "c80146bc-0b95-4f20-aa1c-62f6258d2aae", "1T", "BROWN RUDNICK LLP", 287895, "APOTEX CORPORATION", 2019, "first_quarter", "HCR", "Public Law 115-52, Section 808, relating to the Competitive Generic Therapy designation;  President's FY19 budget proposal relating to generic drug 180-Day exclusivity", "HOUSE OF REPRESENTATIVES,SENATE", 0, 1, "2019-02-05T14:05:01.903000-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2260510"], "units": {}, "query_ms": 1.0746209882199764, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}